5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures

Med Oncol Tumor Pharmacother. 1991;8(2):75-8. doi: 10.1007/BF02988857.

Abstract

Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C. This study reports the preliminary results of a multistep program aimed at the prospective clinical application of the assay. At present this in vitro experience was performed in parallel with a clinical trial carried out with the same drugs. The in vitro activity of the two anticancer agents is in agreement with the response rate reported in monochemotherapy; our data would suggest an increase of responses using the combination of fluorouracil and mitomycin in comparison to single drug therapy. A low cosensitivity rate and a high number of cases sensitive to one drug but resistant to the other, account for the use of this test as screening of active drugs in the individual patient.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • DNA, Neoplasm / biosynthesis
  • DNA, Neoplasm / drug effects
  • Drug Screening Assays, Antitumor
  • Fluorouracil / administration & dosage
  • Humans
  • Mitomycin / administration & dosage
  • RNA, Neoplasm / biosynthesis
  • RNA, Neoplasm / drug effects
  • Tumor Cells, Cultured / drug effects

Substances

  • DNA, Neoplasm
  • RNA, Neoplasm
  • Mitomycin
  • Fluorouracil